June 26, 2005 -- Even though the last two days of last week were negative in a headline grabbing way, biotech remains pretty much in the middle of its 18-month trading range, which is also true for the markets as a whole. Last week, the Centient Biotech 200 lost 46 points, a drop of 1.36%. Leading biotech to the upside last week was Corautus, a gene therapy company with two drugs in clinical trials, Genaissance Pharma rose after receiving a buy-out offer, Vivus shot higher on good news about its impotence drug, Regeneron climbed on positive news about an autoinflammatory drug, and Momenta took advantage of an analyst upgrade to move up. More details...
